JP6835727B2 - Ｉｒａｋ１／４阻害剤としての大環状化合物及びその使用 - Google Patents
Ｉｒａｋ１／４阻害剤としての大環状化合物及びその使用 Download PDFInfo
- Publication number
- JP6835727B2 JP6835727B2 JP2017540605A JP2017540605A JP6835727B2 JP 6835727 B2 JP6835727 B2 JP 6835727B2 JP 2017540605 A JP2017540605 A JP 2017540605A JP 2017540605 A JP2017540605 A JP 2017540605A JP 6835727 B2 JP6835727 B2 JP 6835727B2
- Authority
- JP
- Japan
- Prior art keywords
- mmol
- pyrazole
- compound
- ring
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CCN(*)C(C(CCCCCC1)CC1N(C(C1=CC=CC=CC(c2c[n](****C)nc2)=CC=C1)=O)O*)=O Chemical compound CCN(*)C(C(CCCCCC1)CC1N(C(C1=CC=CC=CC(c2c[n](****C)nc2)=CC=C1)=O)O*)=O 0.000 description 8
- WACOUYNRVIVTFS-YGIGUCEYSA-N C/C=C(\C=C/CCN(C)CCNC(c1n[n](C)cc1NC1=O)=O)/c2nc1ccc2 Chemical compound C/C=C(\C=C/CCN(C)CCNC(c1n[n](C)cc1NC1=O)=O)/c2nc1ccc2 WACOUYNRVIVTFS-YGIGUCEYSA-N 0.000 description 1
- SZNFKIVLPFAUSW-OTJLIBECSA-N C/N=C(\C(\NC(c1cccc(-c2c[n](CCCCCCN3)cc2)n1)=O)=C/CC1CC[IH]CC1)/C3=O Chemical compound C/N=C(\C(\NC(c1cccc(-c2c[n](CCCCCCN3)cc2)n1)=O)=C/CC1CC[IH]CC1)/C3=O SZNFKIVLPFAUSW-OTJLIBECSA-N 0.000 description 1
- LOCGLRNYGMVDEM-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1[n]1nc(C)c(N)c1)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1[n]1nc(C)c(N)c1)=O LOCGLRNYGMVDEM-UHFFFAOYSA-N 0.000 description 1
- YHEYEKRQHSTNFV-NBVRZTHBSA-N CC(C)(C)OC(N/C=C(\CN)/c1cc(C(Nc2c[n](C3CCOCC3)nc2C(OC)=O)=O)ccc1)=O Chemical compound CC(C)(C)OC(N/C=C(\CN)/c1cc(C(Nc2c[n](C3CCOCC3)nc2C(OC)=O)=O)ccc1)=O YHEYEKRQHSTNFV-NBVRZTHBSA-N 0.000 description 1
- HZPXVZBDHAGKTF-HMMYKYKNSA-N CC(CN=C1C(NCCCN(C)CCCC(C)/C=C(\C=C)/c2nc3ccc2)=O)C=C1NC3=O Chemical compound CC(CN=C1C(NCCCN(C)CCCC(C)/C=C(\C=C)/c2nc3ccc2)=O)C=C1NC3=O HZPXVZBDHAGKTF-HMMYKYKNSA-N 0.000 description 1
- IPLMSBHJISDLTK-UHFFFAOYSA-N CCCCCNC(C1NN(C)CC1NC(c1cccc(C(C=CCC2C)=CN2C=C=C)n1)=O)=O Chemical compound CCCCCNC(C1NN(C)CC1NC(c1cccc(C(C=CCC2C)=CN2C=C=C)n1)=O)=O IPLMSBHJISDLTK-UHFFFAOYSA-N 0.000 description 1
- PNJLTYSJTZUFPW-UHFFFAOYSA-N CS(C(CC1)CCC1C(C=C1NC(c2cccc(-c3c[n](CCCCCCN4)cc3)n2)=O)N=C1C4=C)(=O)=O Chemical compound CS(C(CC1)CCC1C(C=C1NC(c2cccc(-c3c[n](CCCCCCN4)cc3)n2)=O)N=C1C4=C)(=O)=O PNJLTYSJTZUFPW-UHFFFAOYSA-N 0.000 description 1
- VFKSBPDPFVEQDD-DUXPYHPUSA-N C[n](cc1NC(c2cccc(-c3c[n](CCC/C=C/CN4)nc3)n2)=O)nc1C4=O Chemical compound C[n](cc1NC(c2cccc(-c3c[n](CCC/C=C/CN4)nc3)n2)=O)nc1C4=O VFKSBPDPFVEQDD-DUXPYHPUSA-N 0.000 description 1
- WHFKPHNLHTXXRK-UHFFFAOYSA-N C[n](cc1NC(c2cccc(-c3c[n](CCCCN4)nc3)n2)=O)nc1C4=O Chemical compound C[n](cc1NC(c2cccc(-c3c[n](CCCCN4)nc3)n2)=O)nc1C4=O WHFKPHNLHTXXRK-UHFFFAOYSA-N 0.000 description 1
- YDGZWPQETACZKG-UHFFFAOYSA-N Cc1c[n](C2CCNCC2)nc1C=C Chemical compound Cc1c[n](C2CCNCC2)nc1C=C YDGZWPQETACZKG-UHFFFAOYSA-N 0.000 description 1
- VPIPHCYJMTYWDB-UHFFFAOYSA-N Cc1n[n](C2CCOCC2)cc1N Chemical compound Cc1n[n](C2CCOCC2)cc1N VPIPHCYJMTYWDB-UHFFFAOYSA-N 0.000 description 1
- XTYIUILEPOTHBL-BHQXMWAMSA-N N=C/C(/c1nc(C(Nc2c[n](C3CCOCC3)nc22)=O)ccc1)=C\NCCCSCCNC2=O Chemical compound N=C/C(/c1nc(C(Nc2c[n](C3CCOCC3)nc22)=O)ccc1)=C\NCCCSCCNC2=O XTYIUILEPOTHBL-BHQXMWAMSA-N 0.000 description 1
- VXBUFWQNCCDBAK-UHFFFAOYSA-N O=C(c1n[n](C2CCOCC2)cc1NC(c1cccc(-c2c[n](CC3)cc2)n1)=O)NCCS3=O Chemical compound O=C(c1n[n](C2CCOCC2)cc1NC(c1cccc(-c2c[n](CC3)cc2)n1)=O)NCCS3=O VXBUFWQNCCDBAK-UHFFFAOYSA-N 0.000 description 1
- QFVLIPVOWSJFPF-UHFFFAOYSA-N O=C(c1n[n](C2CCOCC2)cc1NC1=O)NCCCCCC[n](cc2)cc2-c2cccc1n2 Chemical compound O=C(c1n[n](C2CCOCC2)cc1NC1=O)NCCCCCC[n](cc2)cc2-c2cccc1n2 QFVLIPVOWSJFPF-UHFFFAOYSA-N 0.000 description 1
- QSQDLNLAWYQLMR-UHFFFAOYSA-N OCCCC(CC1)CCC1[n](cc1NC(c2cccc(-c3c[n](CCCCCCN4)nc3)n2)=O)nc1C4=O Chemical compound OCCCC(CC1)CCC1[n](cc1NC(c2cccc(-c3c[n](CCCCCCN4)nc3)n2)=O)nc1C4=O QSQDLNLAWYQLMR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Dermatology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562112374P | 2015-02-05 | 2015-02-05 | |
| US62/112,374 | 2015-02-05 | ||
| PCT/US2016/016709 WO2016127025A1 (en) | 2015-02-05 | 2016-02-05 | Macrocyclic compounds as irak1/4 inhibitors and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018506531A JP2018506531A (ja) | 2018-03-08 |
| JP2018506531A5 JP2018506531A5 (OSRAM) | 2019-03-14 |
| JP6835727B2 true JP6835727B2 (ja) | 2021-02-24 |
Family
ID=55436167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017540605A Expired - Fee Related JP6835727B2 (ja) | 2015-02-05 | 2016-02-05 | Ｉｒａｋ１／４阻害剤としての大環状化合物及びその使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9708324B2 (OSRAM) |
| EP (1) | EP3253764B1 (OSRAM) |
| JP (1) | JP6835727B2 (OSRAM) |
| KR (1) | KR20170109546A (OSRAM) |
| CN (1) | CN107849055B (OSRAM) |
| AU (1) | AU2016215185B2 (OSRAM) |
| BR (1) | BR112017013677B1 (OSRAM) |
| CA (1) | CA2970534C (OSRAM) |
| ES (1) | ES2886577T3 (OSRAM) |
| IL (1) | IL253520B (OSRAM) |
| MX (1) | MX383363B (OSRAM) |
| NZ (1) | NZ732538A (OSRAM) |
| RU (1) | RU2730016C2 (OSRAM) |
| SG (1) | SG11201704628VA (OSRAM) |
| WO (1) | WO2016127025A1 (OSRAM) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015371251B2 (en) | 2014-12-23 | 2020-06-11 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| CN107427521B (zh) | 2015-03-27 | 2021-08-03 | 达纳-法伯癌症研究所股份有限公司 | 细胞周期蛋白依赖性激酶的抑制剂 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| US11254667B2 (en) | 2016-08-17 | 2022-02-22 | Children's Hospital Medical Center | Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors |
| US11542261B2 (en) | 2016-08-17 | 2023-01-03 | Children's Hospital Medical Center | Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors |
| TWI733982B (zh) | 2017-02-16 | 2021-07-21 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒衍生物 |
| WO2019111218A1 (en) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Novel heterocyclic compounds as irak4 inhibitors |
| JP7590185B2 (ja) * | 2018-06-25 | 2024-11-26 | ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド | Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用 |
| TWI721483B (zh) | 2018-07-13 | 2021-03-11 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
| CA3224985C (en) | 2018-07-31 | 2025-11-18 | Loxo Oncology, Inc. | SPRAY-DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE |
| WO2020140098A1 (en) | 2018-12-28 | 2020-07-02 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 and uses thereof |
| MA55517A (fr) * | 2019-03-28 | 2022-02-09 | Lupin Ltd | Composés macrocycliques utilisés en tant qu'agonistes sting |
| CN111603471B (zh) * | 2020-06-24 | 2021-07-09 | 山东省科学院生物研究所 | 一种邻二氮杂环化合物在制备抑制tlr4受体的药物中的用途 |
| US20230295146A1 (en) * | 2020-07-24 | 2023-09-21 | The University Of Rochester | Inhibitors of interleukin-1 receptor-associated kinases 1 and 4 |
| EP4223368B1 (en) | 2020-09-30 | 2025-05-21 | Asahi Kasei Pharma Corporation | Macrocyclic compounds incorporating piperidine and quinoline or qunaxoline as irak-4 inhibitors for the treatment of inflammatory conditions |
| US20260034112A1 (en) * | 2022-08-01 | 2026-02-05 | Children's Hospital Medical Center | Multi-cyclic irak1 and irak4 inhibiting compounds and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008520670A (ja) * | 2004-11-17 | 2008-06-19 | メルク エンド カムパニー インコーポレーテッド | アルツハイマー病の治療のための大環状第三アミンβ−セクレターゼ阻害剤 |
| MY169441A (en) * | 2004-12-08 | 2019-04-11 | Janssen Pharmaceutica Nv | 2,4, (4,6) pyrimidine derivatives |
| US8933066B2 (en) * | 2011-04-14 | 2015-01-13 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US9586948B2 (en) * | 2012-10-08 | 2017-03-07 | Merck Sharp & Dohme Corp. | Inhibitors of IRAK4 activity |
| RU2660435C2 (ru) * | 2013-02-07 | 2018-07-06 | Мерк Патент Гмбх | Макроциклические производные пиридазинона |
| WO2014143672A1 (en) * | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Macrocyclic compounds as irak4 inhibitors for the treatment of inflammatory diseases |
-
2016
- 2016-02-05 JP JP2017540605A patent/JP6835727B2/ja not_active Expired - Fee Related
- 2016-02-05 NZ NZ732538A patent/NZ732538A/en not_active IP Right Cessation
- 2016-02-05 CA CA2970534A patent/CA2970534C/en active Active
- 2016-02-05 EP EP16706472.4A patent/EP3253764B1/en active Active
- 2016-02-05 US US15/016,569 patent/US9708324B2/en not_active Expired - Fee Related
- 2016-02-05 BR BR112017013677-5A patent/BR112017013677B1/pt not_active IP Right Cessation
- 2016-02-05 ES ES16706472T patent/ES2886577T3/es active Active
- 2016-02-05 KR KR1020177020263A patent/KR20170109546A/ko not_active Ceased
- 2016-02-05 SG SG11201704628VA patent/SG11201704628VA/en unknown
- 2016-02-05 AU AU2016215185A patent/AU2016215185B2/en not_active Ceased
- 2016-02-05 WO PCT/US2016/016709 patent/WO2016127025A1/en not_active Ceased
- 2016-02-05 CN CN201680018713.8A patent/CN107849055B/zh not_active Expired - Fee Related
- 2016-02-05 MX MX2017009625A patent/MX383363B/es unknown
- 2016-02-05 RU RU2017130762A patent/RU2730016C2/ru active
-
2017
- 2017-06-12 US US15/620,049 patent/US9815836B2/en not_active Expired - Fee Related
- 2017-07-17 IL IL253520A patent/IL253520B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| EP3253764B1 (en) | 2021-06-09 |
| MX383363B (es) | 2025-03-13 |
| IL253520B (en) | 2020-07-30 |
| MX2017009625A (es) | 2017-11-20 |
| BR112017013677A2 (pt) | 2018-01-09 |
| WO2016127025A1 (en) | 2016-08-11 |
| SG11201704628VA (en) | 2017-07-28 |
| CN107849055B (zh) | 2020-08-07 |
| RU2017130762A (ru) | 2019-03-05 |
| KR20170109546A (ko) | 2017-09-29 |
| US9815836B2 (en) | 2017-11-14 |
| NZ732538A (en) | 2022-04-29 |
| RU2017130762A3 (OSRAM) | 2019-04-30 |
| CA2970534A1 (en) | 2016-08-11 |
| AU2016215185B2 (en) | 2020-06-25 |
| EP3253764A1 (en) | 2017-12-13 |
| RU2730016C2 (ru) | 2020-08-14 |
| US9708324B2 (en) | 2017-07-18 |
| US20170275284A1 (en) | 2017-09-28 |
| AU2016215185A1 (en) | 2017-06-29 |
| US20160229856A1 (en) | 2016-08-11 |
| IL253520A0 (en) | 2017-09-28 |
| ES2886577T3 (es) | 2021-12-20 |
| CA2970534C (en) | 2023-08-29 |
| JP2018506531A (ja) | 2018-03-08 |
| CN107849055A (zh) | 2018-03-27 |
| BR112017013677B1 (pt) | 2023-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2730016C2 (ru) | Макроциклические соединения в качестве irak1/4 ингибиторов и их применение | |
| JP6920202B2 (ja) | Ｉｒａｋ阻害剤としてのピリダジノン大環状化合物及びその使用 | |
| TWI846690B (zh) | 作為第ii型irak抑制劑之雜芳化合物及其用途 | |
| JP6787892B2 (ja) | Ｉｒａｋインヒビターとしてのヘテロアリール化合物及びその使用 | |
| CA2985859A1 (en) | Tbk/ikk.epsilon. inhibitor compounds and uses thereof | |
| JP7316288B2 (ja) | Ｉｒａｋ阻害剤としてのキノリン化合物及びその使用 | |
| HK1247918A1 (en) | Macrocyclic compounds as irak1/4 inhibitors and uses thereof | |
| HK1247918B (zh) | 用作irak1/4抑制剂的大环化合物及其用途 | |
| HK40043591A (en) | Heteroaryl compounds as type ii irak inhibitors and uses thereof | |
| NZ732527B2 (en) | Pyridazinone macrocycles as irak inhibitors and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190204 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190204 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20191128 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200107 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200403 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200707 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201117 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201203 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210105 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210204 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6835727 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |